NDA 020849 · Baxter Hlthcare
Prosol 20% Sulfite Free In Plastic Container
Amino Acids · Injection · Amino Acid
Last checked: Nov 20, 2026Latest source record: Sep 23, 2020 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1998
Aug 26, 1998
Approved uses
1
Original approval plus efficacy supplements
Registered trials
30,323
6,603 Phase 3, 2,682 recruiting
FAERS reports
13
9 serious, 2 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Oct 7, 2020.
PROSOL is indicated as a source of amino acids for patients requiring parenteral nutrition when oral or enteral nutrition is not possible, insufficient, or contraindicated. PROSOL may be used to treat negative nitrogen balance in patients. • PROSOL is indicated as a source of amino acids for patients requiring parenteral nutrition when oral or enteral nutrition is not possible, insufficient, or contraindicated. PROSOL may be used to treat negative nitrogen balance in patents. ( 1 )
Mechanism: PROSOL is used as a supplement of nutrition in patients, providing amino acids parenterally. The amino acids provide the structural units that make up proteins and are used to synthesize proteins and other biomolecules or are oxidized to urea and carbon dioxide as a source of energy.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
1 products under this application
- PROSOL 20% SULFITE FREE IN PLASTIC CONTAINER · AMINO ACIDS 20% (20GM/100ML) · INJECTABLE, INJECTION · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Amino Acids" as an intervention, any sponsor and status, largest first.
- Effectiveness of An Influenza/COVID-19 Vaccine (mCombriax [mRNA-1083]) in Adults ≥ 65 YearsPivotal-lookingNot yet recruiting
Tor Biering-SørensenAcademic, hospital or other
NCT07790523 · 410,000 participants (planned) · Start Sep 1, 2026 · Primary completion May 31, 2028
Drug: mCombriax® (mRNA-1083); Efluelda® (TIV-HD) and Spikevax® (mRNA-1273) · For: COVID-19; Influenza
Sites: Hellerup, Denmark; Søborg, Denmark; Santiago de Compostela, Spain
- Community Level Interventions for Pre-eclampsiaPivotal-lookingCompleted
University of British ColumbiaAcademic, hospital or other
NCT01911494 · 87,500 participants (planned) · Start Sep 2013 · Primary completion May 2018
Drug: Magnesium Sulfate; Methyldopa · For: Pre-eclampsia; Hypertension, Pregnancy Induced
Sites: Belagavi, India; Maputo, Mozambique; Sagamu, Nigeria · 4 sites in all
- Randomised Evaluation of COVID-19 TherapyPivotal-lookingRecruiting
University of OxfordAcademic, hospital or other
NCT04381936 · 70,000 participants (planned) · Start Mar 19, 2020 · Primary completion Sep 30, 2028
Drug: Lopinavir-Ritonavir; Corticosteroid and 20 more · For: Pneumonia
Sites: Brussels, Belgium; Tallinn, Estonia; Paris, France · 16 sites in all
- Filgrastim-Mobilized Stem Cells for Transplantation Using Unrelated DonorsPivotal-lookingRecruiting
Center for International Blood and Marrow Transplant ResearchResearch network
NCT00785525 · 60,000 participants (planned) · Start Feb 1997 · Primary completion Jan 2030
Drug: Filgrastim · For: Healthy
Sites: Boca Raton, Florida; Rockville, Maryland; Minneapolis, Minnesota · 4 sites in all
- Study to Describe the Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy IndividualsPivotal-lookingCompleted
BioNTech SEIndustry
NCT04368728 · 46,969 participants · Start Apr 29, 2020 · Primary completion Feb 10, 2023
Drug: BNT162b1; BNT162b2 and 1 more · For: SARS-CoV-2 Infection; COVID-19
Sites: Athens, Alabama; Birmingham, Alabama; Huntsville, Alabama · 175 sites in all
- Effectiveness of mRNA-1273 Variant-Containing Vaccine Formulation Against Severe Outcomes in Adults Aged 50-64 Years Without Risk Factors for Severe COVID-19Pivotal-lookingCompleted
Tor Biering-SørensenAcademic, hospital or other
NCT07279766 · 41,060 participants · Start Dec 11, 2025 · Primary completion Aug 26, 2026
Drug: mRNA-1273 (Moderna COVID-19 vaccine) · For: COVID-19
Sites: Hellerup, Denmark; Søborg, Denmark
- Prevention of Infections in Cardiac Surgery (PICS): a Cluster-randomized Factorial Cross-over TrialPivotal-lookingNot yet recruiting
Hamilton Health Sciences CorporationAcademic, hospital or other
NCT06567808 · 38,000 participants (planned) · Start Mar 1, 2026 · Primary completion Apr 30, 2028
Drug: Cefazolin; Vancomycin · For: Infection, Surgical Site
- A Study to Evaluate Efficacy, Safety, and Immunogenicity of mRNA-1273 Vaccine in Adults Aged 18 Years and Older to Prevent COVID-19Pivotal-lookingCompleted
ModernaTX, Inc.Moderna (MRNA)
NCT04470427 · 30,415 participants · Start Jul 27, 2020 · Primary completion Dec 29, 2022
Drug: mRNA-1273; Placebo · For: SARS-CoV-2
Sites: Birmingham, Alabama; Chandler, Arizona; Glendale, Arizona · 100 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- sepsis3
- back pain2
- body temperature increased2
- cardiac arrest2
- death2
- headache2
- malaise2
- nausea2
- off label use2
- vomiting2
- agitation1
- anaemia1
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2008 | 1 |
| 2014 | 1 |
| 2016 | 1 |
| 2017 | 1 |
| 2018 | 1 |
| 2019 | 5 |
| 2024 | 2 |
| 2026 | 1 |
Recalls
1 FDA enforcement reports for this application.
Aug 4, 2014 · Class II · Terminated
Presence of Particulate Matter: identification of particulates in a retention sample that have been identified as a mixture of the amino acid leucine and inorganic material (containing iron, silicone and chlorine).
Shortages
FDA's drug shortage list.
Current · updated Nov 18, 2026
PROSOL 20% SULFITE FREE IN PLASTIC CONTAINER, Injection, 2.76 g/100 mL; 1.96 g/100 mL; 600 mg/100 mL; 1.02 g/100 mL; 2.06 g/100 mL; 1.18 g/100 mL; 1.08 g/100 mL; 1.08 g/100 mL; 1.35 g/100 mL; 760 mg/100 mL; 1 g/100 mL;...
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Efficacy of dietary supplements on improving sleep quality: a systematic review and meta-analysis.
Chan V, Lo K · Postgrad Med J 2022 · Meta-Analysis, Systematic Review
- β-alanine supplementation to improve exercise capacity and performance: a systematic review and meta-analysis.
Saunders B, Elliott-Sale K, Artioli GG, et al. · Br J Sports Med 2017 · Meta-Analysis, Systematic Review
- Nutritional interventions to improve muscle mass, muscle strength, and physical performance in older people: an umbrella review of systematic reviews and meta-analyses.
Gielen E, Beckwée D, Delaere A, et al. · Nutr Rev 2021 · Meta-Analysis, Systematic Review
- Protein interventions augment the effect of resistance exercise on appendicular lean mass and handgrip strength in older adults: a systematic review and meta-analysis of randomized controlled trials.
Kirwan RP, Mazidi M, Rodríguez García C, et al. · Am J Clin Nutr 2022 · Meta-Analysis, Research Support, Non-U.S. Gov't
- Biomarkers shared by frailty and sarcopenia in older adults: A systematic review and meta-analysis.
Picca A, Coelho-Junior HJ, Calvani R, et al. · Ageing Res Rev 2022 · Meta-Analysis, Research Support, Non-U.S. Gov't
- Metabolomics in Prediabetes and Diabetes: A Systematic Review and Meta-analysis.
Guasch-Ferré M, Hruby A, Toledo E, et al. · Diabetes Care 2016 · Meta-Analysis, Systematic Review
Sponsor: Baxter Hlthcare
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.